<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672854</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00007587</org_study_id>
    <secondary_id>TPN</secondary_id>
    <nct_id>NCT00672854</nct_id>
  </id_info>
  <brief_title>Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in Intensive Care Unit Patients</brief_title>
  <acronym>TPN 2</acronym>
  <official_title>StudyComparing a Soybean Oil-Based vs Olive Oil-Based Lipid Emulsion: Effects on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function,Insulin Sensitivity and Carb Metabolism Intensive Care Unit Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many hospitalized patients who are malnourished or not eating receive intravenous feeding or
      total parenteral nutrition (TPN). Despite improving nutrition, TPN may increase the risk of
      infections and hospital complications. We do not know why TPN increases hospital
      complications, but it may be caused by the high sugar or fat content in TPN solutions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares the effect of a soybean oil-based versus an olive oil-based lipid
      emulsion in healthy volunteers and in critically ill patients. In healthy volunteers, your
      blood sugar levels, blood vessel function, and your ability to fight infections will be
      examined. In ICU patients, we examines whether use of the olive oil-based lipid emulsion may
      decrease the risk of infection and hospital complications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Nosocomial Infection Rate</measure>
    <time_frame>Up to 28 days post-randomization</time_frame>
    <description>Culture-proven infection including: wound, drain, respiratory tract, bloodstream infection (BSI), and urinary tract infections while receiving PN and during current hospitalization after study entry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic Nervous System</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Total Parenteral nutrition (TPN) given Intralipid 20%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who require TPN receiving Intralipid (soybean-based)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total parenteral nutrition (TPN) given ClinOleic 20%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN subjects receive ClinOleic 20% (olive oil based)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ClinOleic</intervention_name>
    <description>TPN with ClinOleic (20%)</description>
    <arm_group_label>Total parenteral nutrition (TPN) given ClinOleic 20%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>TPN with Intralipid (20%)</description>
    <arm_group_label>Total Parenteral nutrition (TPN) given Intralipid 20%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age: 18 - 80 years when initiating PN

          -  In medical/surgical ICU

          -  Has central venous access to administer PN

          -  Anticipated to receive PN ≥ 5 days

        Exclusion criteria:

          -  Enrolled in an investigative study within the last 30 days prior to study entry

          -  Female patients: pregnant or breast feeding

          -  Has clinical sepsis (defined as mean arterial pressure (MAP) &lt; 60 mmHg on ≥ 2
             occasions and unstable BP despite pressor support) within 24 hours prior to study
             entry

          -  Has known cirrhosis or total bilirubin ≥ 10.0 mg/dL

          -  Has chronic renal failure (defined as requirement for hemodialysis or peritoneal
             dialysis therapy), or creatinine ≥ 3.5 mg/dL without CRRT, or requires acute
             post-operative dialysis

          -  Has an active malignancy (defined as requiring chemotherapy, radiation, and/or
             surgical intervention within 90 days prior to study entry) (excluding non-melanoma
             skin cancer)

          -  Has known AIDS

          -  Has a terminal illness (life expectancy &lt; 7 days)

          -  Has undergone organ transplantation

          -  Has received PN with lipid within 48 hours prior to study entry

          -  Has mental disability to understand the scope and possible consequences of the study
             and the legally authorized representative is unavailable

          -  Has a baseline serum triglyceride &gt; 400 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>July 2, 2014</results_first_submitted>
  <results_first_submitted_qc>July 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <last_update_submitted>July 2, 2014</last_update_submitted>
  <last_update_submitted_qc>July 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>parenteral nutrition</keyword>
  <keyword>lipid emulsion</keyword>
  <keyword>nosocomial infection</keyword>
  <keyword>mortality</keyword>
  <keyword>endothelial function</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>immune function</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>carbohydrate metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Total Parenteral Nutrition (TPN) Given Intralipid 20%</title>
          <description>TPN subjects receive Intralipid (soybean-based)
Intralipid: TPN with Intralipid (20%)</description>
        </group>
        <group group_id="P2">
          <title>Total Parenteral Nutrition (TPN) Given ClinOleic 20%</title>
          <description>TPN subjects receive ClinOleic 20% (olive oil based)
ClinOleic: TPN with ClinOleic (20%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Parenteral Nutrition (TPN) Given Intralipid 20%</title>
          <description>TPN subjects receive Intralipid (soybean-based)
Intralipid: TPN with Intralipid (20%)</description>
        </group>
        <group group_id="B2">
          <title>Total Parenteral Nutrition (TPN) Given ClinOleic 20%</title>
          <description>TPN subjects receive ClinOleic 20% (olive oil based)
ClinOleic: TPN with ClinOleic (20%)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="15"/>
                    <measurement group_id="B2" value="46.4" spread="19"/>
                    <measurement group_id="B3" value="48.9" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Nosocomial Infection Rate</title>
        <description>Culture-proven infection including: wound, drain, respiratory tract, bloodstream infection (BSI), and urinary tract infections while receiving PN and during current hospitalization after study entry</description>
        <time_frame>Up to 28 days post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Parenteral Nutrition (TPN) Given Intralipid 20%</title>
            <description>TPN subjects receive Intralipid 20% (soybean-based)
Intralipid: TPN with Intralipid (20%)</description>
          </group>
          <group group_id="O2">
            <title>Total Parenteral Nutrition (TPN) Given ClinOleic 20%</title>
            <description>TPN subjects receive ClinOleic 20% (olive oil based)
ClinOleic: TPN with ClinOleic (20%)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Nosocomial Infection Rate</title>
          <description>Culture-proven infection including: wound, drain, respiratory tract, bloodstream infection (BSI), and urinary tract infections while receiving PN and during current hospitalization after study entry</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Function</title>
        <time_frame>2-year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers</title>
        <time_frame>2-year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress</title>
        <time_frame>2-year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Autonomic Nervous System</title>
        <time_frame>2-year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <time_frame>2-year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality</title>
        <time_frame>2-year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Total Parenteral Nutrition (TPN) Given Intralipid 20%</title>
          <description>TPN subjects receive Intralipid 20% (soybean-based)
Intralipid: TPN with Intralipid (20%)</description>
        </group>
        <group group_id="E2">
          <title>Total Parenteral Nutrition (TPN) Given ClinOleic 20%</title>
          <description>TPN subjects receive ClinOleic 20% (olive oil based)
ClinOleic: TPN with ClinOleic (20%)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Vein irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

